# To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy Subjects

> **NCT05413161** · PHASE1 · COMPLETED · sponsor: **Kashiv BioSciences, LLC** · enrollment: 306 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** ADL-018
- **BIOLOGICAL:** US-licensed XOLAIR
- **BIOLOGICAL:** EU-Approved XOLAIR

## Key facts

- **NCT ID:** NCT05413161
- **Lead sponsor:** Kashiv BioSciences, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-07
- **Primary completion:** 2023-02-21
- **Final completion:** 2023-06-30
- **Target enrollment:** 306 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05413161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05413161, "To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05413161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*